FutuRx: A Unique Model for Developing Breakthrough Medicines
FutuRx is a biotech incubator that stands out due to its strong foundation and unique operational model. Established by three leading global healthcare players – Takeda (Takeda Ventures Inc.), Johnson & Johnson (JJDC), and OrbiMed Israel Partners, the firm brings together the expertise and capabilities of its founders to transform breakthrough discoveries into novel medicines. Located at 2 Ilan Ramon Ness Ziona, Israel 7403635, FutuRx specializes in biotechnology research and leverages its access to the Israeli biotech industry, as well as leading research institutes in Israel and worldwide, to identify and develop highly innovative technologies.
The collaboration of these three global healthcare giants is the cornerstone of FutuRx's success. Experts from Takeda, J&J, and OrbiMed are deeply involved in the project selection process and during the incubator period of each company. This ensures a clear impact on the efficient translation of innovative research into clinically meaningful products. FutuRx's unique model positions it as a crucial player in the biotechnology research industry.
Takeda Ventures Inc., a subsidiary of Japanese multinational pharmaceutical company Takeda, is known for its commitment to discovering, developing, and delivering innovative, high-quality medicines. Johnson & Johnson, a multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods, is well-recognized for its comprehensive and diverse range of health-related products. OrbiMed Israel Partners, an affiliate of the world's largest healthcare-dedicated investment firm OrbiMed, focuses on investing in Israeli healthcare companies and technologies. By combining the strengths of these organizations, FutuRx offers a unique and unparalleled incubation experience for biotech startups.
FutuRx provides a supportive environment that allows biotech startups to thrive and develop innovative solutions. Its location in Israel, a country known for its cutting-edge technological advancements and vibrant biotech industry, adds to the company's appeal. By tapping into the wealth of knowledge and resources from its founders and the Israeli biotech ecosystem, FutuRx can identify promising technologies and help bring them to market.
To learn more about FutuRx and its innovative approach to biotechnology research, please visit http://www.futurx.co.il.